Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV001811748 | SCV002050020 | likely benign | not provided | 2021-10-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002542336 | SCV003517434 | likely benign | Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection | 2022-06-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004040889 | SCV003742089 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2022-03-25 | criteria provided, single submitter | clinical testing | The c.1653C>T (p.G551G) alteration is located in exon 14 (coding exon 13) of the FBN1 gene. This alteration consists of a C to T substitution at nucleotide position 1653. This nucleotide substitution does not change the amino acid at codon 551. However, this change occurs in the last nucleotide of Exon 14 (c.1589_1714) which makes it likely to have some effect on normal mRNA splicing. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
All of Us Research Program, |
RCV004009070 | SCV004817193 | likely benign | Marfan syndrome | 2023-02-24 | criteria provided, single submitter | clinical testing |